Analysts think MREO stock price could increase by 177%
Mar 20, 2025, 11:25 AM
-10.85%
What does MREO do
Mereo BioPharma Group Plc develops therapeutics for oncology and rare diseases, focusing on setrusumab for osteogenesis imperfecta and alvelestat for alpha-1-antitrypsin deficiency. The company also has oncology candidates and partnered programs like Navicixizumab.
10 analysts think MREO stock price will increase by 176.74%. The current median analyst target is $7.14 compared to a current stock price of $2.58. The lowest analysts target is $5.76 and the highest analyst target is $10.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
